Stocks · News reference
Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35
Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of
BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor, in patients with elevated cardiovascular risk and systemic inflammation. Topline data is anticipated in the second half of 2026. The company also announced participation in three upcoming investor conferences in September 2026.